GO:0015849 organic acid transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015849 organic acid transport describes the directed movement of carbon-containing acidic compounds into, out of, or within cells, typically mediated by transporters or pores.
• Key transporter families include SLC22A7 (OAT2), SLC51A/SLC51B (OSTα/β), and SLC16A2 (MCT8), which handle substrates such as bile acids, nicotinic acid, and thyroid hormone derivatives.
• Dysregulation of organic acid transport is linked to cholestatic liver disease, drug-induced hepatotoxicity, and thyroid hormone disorders.
• Structural studies of OSTα/β have revealed a unique fold and mechanism for bile acid transport, providing a template for understanding related transporters.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for dissecting the causal roles of organic acid transporters in physiology and disease.
• Targeting organic acid transporters can modulate drug delivery and toxicity, making them attractive for pharmacological intervention.
Description
Organic acid transport (GO:0015849) is a fundamental biological process that governs the movement of acidic compounds containing carbon across cellular membranes. This process is essential for nutrient uptake, waste elimination, and drug disposition, and it relies on specialized transporter proteins that facilitate the passage of substrates such as bile acids, nicotinic acid, and thyroid hormone derivatives. The directed movement can occur into, out of, or within cells, often against concentration gradients, and is critical for maintaining metabolic homeostasis. Researchers study organic acid transport to understand its roles in liver function, renal excretion, and systemic hormone regulation, as well as its implications in disease and pharmacology. The transporters involved are members of the solute carrier (SLC) family, including SLC22A7 (OAT2), SLC51A/SLC51B (OSTα/β), and SLC16A2 (MCT8), each with distinct substrate specificities and tissue distributions. Dysregulation of these transporters can lead to cholestasis, hepatotoxicity, and neurological disorders, highlighting their clinical importance. This article provides a comprehensive overview of the mechanisms, key genes, and research methodologies associated with GO:0015849, with a focus on CRISPR-based approaches for functional validation.
organic acid transport At A Glance
| GO ID | GO:0015849 |
|---|---|
| GO term | organic acid transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Directed movement of organic acids across membranes via transporters or pores |
| Substrates | Bile acids, nicotinic acid, thyroid hormone derivatives, other carboxylates |
| Key transporters | SLC22A7, SLC51A, SLC51B, SLC16A2, SLC10A1, ABCC2 |
| Tissue distribution | Liver, kidney, intestine, brain, thyroid |
| Related diseases | Cholestasis, hepatotoxicity, thyroid hormone resistance, drug-induced liver injury |
What Is GO:0015849?
According to the Gene Ontology, organic acid transport (GO:0015849) is defined as the directed movement of organic acids, any acidic compound containing carbon in covalent linkage, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. This process encompasses the translocation of carboxylate-containing molecules, including bile acids, short-chain fatty acids, and amino acid derivatives, across biological membranes. It is a biological process that requires specific transport proteins, often driven by ion gradients or ATP hydrolysis, and is distinct from passive diffusion.
Why Is organic acid transport Important in Cell Biology?
Organic acid transport is vital for numerous physiological processes, including the enterohepatic circulation of bile acids, renal excretion of metabolic waste, and delivery of thyroid hormones to target tissues. It also plays a central role in drug pharmacokinetics, as many therapeutic agents are organic acids that rely on these transporters for absorption, distribution, and elimination. Dysfunction of organic acid transporters is associated with severe pathologies such as progressive familial intrahepatic cholestasis, drug-induced hepatotoxicity, and Allan-Herndon-Dudley syndrome. Understanding the molecular mechanisms of these transporters can inform the development of targeted therapies and improve drug safety profiles.
• Maintains bile acid homeostasis and prevents cholestatic liver injury.
• Facilitates renal excretion of organic anions and drugs.
• Enables thyroid hormone uptake in the brain and other tissues.
• Modulates the pharmacokinetics and toxicity of anionic drugs.
• Involved in the pathogenesis of drug-induced liver injury.
• Provides targets for treating metabolic and neurological disorders.
• Essential for nutrient absorption in the intestine.
• Contributes to the blood-brain barrier transport of organic acids.
• Plays a role in the detoxification of endogenous and exogenous compounds.
• Offers opportunities for CRISPR-based functional genomics.
What Happens During organic acid transport?
Substrate Recognition and Binding
In simple terms: The transporter first grabs the organic acid molecule.
Transporters involved in organic acid transport, such as SLC22A7 (OAT2) and OSTα/β, recognize their substrates through specific binding pockets. For example, SLC22A7 mediates the uptake of nicotinic acid into human liver, demonstrating a high-affinity interaction. Similarly, OSTα/β binds conjugated and unconjugated bile acids with distinct affinities, facilitating their transport across membranes. Structural studies of OSTα/β have revealed a unique fold that accommodates bile acids, providing insights into substrate recognition.
Translocation Across the Membrane
In simple terms: The transporter moves the molecule across the cell membrane.
Once bound, the transporter undergoes conformational changes to translocate the organic acid across the lipid bilayer. This process can be driven by ion gradients or ATP hydrolysis. For instance, OSTα/β functions as a facilitative transporter for bile acids, while other transporters like SLC22A7 operate as exchangers. The directed movement ensures that organic acids are transported into or out of cells according to physiological needs.
Substrate Release and Recycling
In simple terms: The transporter releases the molecule and resets for another round.
After translocation, the organic acid is released into the cytoplasm or extracellular space, and the transporter returns to its original conformation to initiate another cycle. This recycling is essential for continuous transport. For example, OSTα/β releases bile acids into the portal circulation, allowing them to be taken up by hepatocytes. The efficiency of this process is critical for maintaining bile acid homeostasis and preventing cholestasis.
Regulation of Transport Activity
In simple terms: The cell controls how much transport happens.
Organic acid transport is regulated at multiple levels, including transporter expression, post-translational modifications, and substrate availability. For instance, thyroid hormone transporters such as MCT8 are regulated by developmental and hormonal signals. Drug interactions can also modulate transport activity, as seen with OSTα/β and hepatotoxic bile acids. Understanding these regulatory mechanisms is key to predicting drug-drug interactions and disease outcomes.
Key Genes Involved in GO:0015849 organic acid transport
The following genes encode transporters and related proteins that mediate organic acid transport, each with distinct roles and research relevance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC22A7 | Organic anion transporter 2 (OAT2); mediates nicotinic acid and drug uptake in liver | Drug disposition, hepatic clearance studies |
| SLC51A | Organic solute transporter alpha (OSTα); forms heterodimer with OSTβ for bile acid transport | Bile acid homeostasis, cholestasis research |
| SLC51B | Organic solute transporter beta (OSTβ); partner of OSTα | Bile acid transport, drug interactions |
| SLC16A2 | Monocarboxylate transporter 8 (MCT8); thyroid hormone transport | Thyroid hormone disorders, neurodevelopment |
| SLC10A1 | Sodium/taurocholate cotransporting polypeptide (NTCP); bile acid uptake | Hepatology, bile acid metabolism |
| ABCC2 | Multidrug resistance-associated protein 2 (MRP2); canalicular efflux of organic anions | Bile formation, drug-induced liver injury |
| ABCG5 | Sterolin-1; cholesterol and plant sterol efflux | Lipid metabolism, biliary secretion |
| ABCG8 | Sterolin-2; partner of ABCG5 | Cholesterol transport |
| SLC22A1 | Organic cation transporter 1 (OCT1); transports organic cations and some acids | Drug pharmacokinetics |
| SLC22A6 | Organic anion transporter 1 (OAT1); renal organic anion transport | Renal drug excretion |
| SLC22A8 | Organic anion transporter 3 (OAT3); renal and brain transport | Drug clearance, neuropharmacology |
| SLCO1B1 | Organic anion transporting polypeptide 1B1 (OATP1B1); hepatic uptake of organic anions | Statin disposition, drug-drug interactions |
| SLCO1B3 | OATP1B3; hepatic uptake of bile acids and drugs | Liver function, drug transport |
| SLC27A1 | Fatty acid transport protein 1 (FATP1); long-chain fatty acid uptake | Lipid metabolism |
| SLC27A4 | FATP4; intestinal fatty acid transport | Nutrient absorption |
| SLC25A1 | Mitochondrial citrate carrier; transports citrate (organic acid) | Mitochondrial metabolism |
| SLC25A10 | Mitochondrial dicarboxylate carrier; transports malate, succinate | Mitochondrial transport |
How Is organic acid transport Regulated?
Organic acid transport is regulated at transcriptional, post-transcriptional, and post-translational levels. For example, bile acid transporters such as OSTα/β are induced by bile acids via the farnesoid X receptor (FXR), maintaining bile acid homeostasis. Thyroid hormone transporters like MCT8 are regulated by thyroid hormone levels and developmental cues. Drug interactions can inhibit or induce transporter activity, affecting drug disposition and toxicity. Additionally, phosphorylation and ubiquitination can modulate transporter trafficking and stability.
organic acid transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC51A/SLC51B | Cholestasis, bile acid malabsorption | Knockout mouse, patient-derived organoids |
| SLC16A2 | Allan-Herndon-Dudley syndrome | Knockout mouse, iPSC-derived neurons |
| SLC22A7 | Drug-induced liver injury | Hepatocyte-specific knockout, overexpression |
| ABCC2 | Dubin-Johnson syndrome | Knockout rat, HepG2 cells |
| SLC10A1 | Hypercholanemia | Knockout mouse, primary hepatocytes |
Cholestatic Liver Disease
Impaired bile acid transport due to mutations or dysfunction in transporters such as OSTα/β, NTCP, or MRP2 leads to cholestasis, characterized by bile acid accumulation and liver injury. Studies have shown that OSTα/β plays a critical role in protecting hepatocytes from bile acid toxicity, and its inhibition can exacerbate drug-induced liver injury.
Drug-Induced Hepatotoxicity
Many drugs and their metabolites are organic acids that rely on transporters for hepatic uptake and efflux. Inhibition of transporters like OSTα/β or SLC22A7 can lead to intracellular accumulation of toxic bile acids or drugs, causing hepatotoxicity. Understanding these interactions is essential for drug development and safety assessment.
Thyroid Hormone Disorders
Mutations in SLC16A2 (MCT8) cause Allan-Herndon-Dudley syndrome, a severe X-linked neurodevelopmental disorder characterized by impaired thyroid hormone transport into the brain. This highlights the critical role of organic acid transport in hormone signaling and brain development.
Renal Transport Disorders
Defects in renal organic anion transporters such as SLC22A6 and SLC22A8 can affect the excretion of drugs and metabolites, leading to altered pharmacokinetics and potential toxicity. These transporters are also targets for drug-drug interactions.
From organic acid transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC51A impair bile acid transport? | SLC51A knockout cell line (e.g., HepG2) |
| Does a point mutation in SLC16A2 affect thyroid hormone uptake? | SLC16A2 point-mutant knock-in cells |
| Can overexpression of SLC22A7 enhance nicotinic acid uptake? | SLC22A7 overexpression in HEK293 cells |
| What is the subcellular localization of OSTα/β? | Tagged knock-in of SLC51A/SLC51B with GFP |
| Which genes regulate organic acid transport in liver? | CRISPR library screening in hepatocytes |
| Can we model cholestasis in vitro? | Patient iPSC-derived hepatocytes with transporter mutations |
How to Study the organic acid transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled substrate uptake | Transport activity | Kinetic analysis of SLC22A7 |
| Fluorescent bile acid transport | Bile acid transport capacity | OSTα/β function |
| CRISPR knockout screening | Gene essentiality for transport | Identify novel regulators |
| Cryo-EM | Protein structure | Mechanistic insights |
| RNA-seq | Transporter expression levels | Tissue distribution |
| Proteomics | Protein abundance and modifications | Regulation studies |
| Patch clamp | Electrogenic transport | Ion-coupled transporters |
| Live-cell imaging | Subcellular localization | Trafficking of tagged transporters |
Transport Assays
Radiolabeled or fluorescent substrates are used to measure transport activity in cells expressing specific transporters. For example, nicotinic acid uptake via SLC22A7 can be quantified using radiolabeled substrate. Bile acid transport by OSTα/β can be assessed using fluorescent bile acid analogs.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate organic acid transport. For instance, a screen for modulators of bile acid toxicity could reveal novel transporters or regulatory factors.
Structural Biology
Cryo-EM and X-ray crystallography provide high-resolution structures of transporters, revealing substrate binding sites and conformational changes. The structure of OSTα/β has elucidated its unique fold and transport mechanism.
Transcriptomics and Proteomics
RNA-seq and mass spectrometry can profile the expression of organic acid transporters across tissues and conditions, identifying regulatory networks and potential drug targets.
How CRISPR Can Be Used to Study GO:0015849 organic acid transport
Knockout
CRISPR knockout of organic acid transporter genes, such as SLC51A or SLC22A7, can abolish transport activity and reveal their physiological roles. For example, SLC51A knockout cells show impaired bile acid transport, leading to intracellular accumulation and toxicity. Knockout models are essential for validating transporter function and identifying compensatory pathways.
Point Mutation
Introducing disease-associated point mutations into transporter genes using CRISPR can model human disorders. For instance, mutations in SLC16A2 found in Allan-Herndon-Dudley syndrome can be recapitulated in cell lines to study impaired thyroid hormone transport. Point mutation models help dissect structure-function relationships and drug sensitivity.
Knock-in
Knock-in of tagged transporters (e.g., GFP or HA) allows real-time visualization and biochemical purification. Tagged OSTα/β knock-in cells enable tracking of transporter localization and interaction partners. Knock-in of reporter genes under transporter promoters can monitor expression dynamics.
Overexpression
Overexpression of organic acid transporters in heterologous systems, such as HEK293 or CHO cells, facilitates detailed kinetic and pharmacological studies. For example, overexpression of SLC22A7 enhances nicotinic acid uptake, allowing measurement of transport kinetics and inhibitor profiles. Overexpression models are also used for drug screening.
How EDITGENE Supports organic acid transport Research
Researchers studying organic acid transport-related genes often need to determine whether a candidate gene is causally involved in substrate translocation, disease pathogenesis, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of transporters and their regulatory networks.
Contact EDITGENE today to design your custom CRISPR model for organic acid transport research.
Frequently Asked Questions About organic acid transport
What is organic acid transport?
Organic acid transport (GO:0015849) is the directed movement of acidic carbon-containing compounds across cell membranes, mediated by transporters or pores.
What genes are involved in organic acid transport?
Key genes include SLC22A7, SLC51A, SLC51B, SLC16A2, SLC10A1, ABCC2, and others encoding solute carriers and ABC transporters.
How is organic acid transport regulated?
It is regulated by nuclear receptors like FXR, hormones, and post-translational modifications that affect transporter expression and activity.
What diseases are linked to organic acid transport defects?
Cholestasis, drug-induced hepatotoxicity, Allan-Herndon-Dudley syndrome, and renal transport disorders.
Which transporters handle bile acids?
OSTα/β (SLC51A/SLC51B), NTCP (SLC10A1), and MRP2 (ABCC2) are major bile acid transporters.
How can I study organic acid transport in the lab?
Use radiolabeled or fluorescent substrates, CRISPR knockout/knock-in models, and structural biology techniques.
What is the role of SLC22A7 in drug transport?
SLC22A7 (OAT2) mediates the hepatic uptake of nicotinic acid and other organic anions, influencing drug disposition.
Can CRISPR be used to model organic acid transport diseases?
Yes, CRISPR knockout, point mutation, and knock-in models can recapitulate disease phenotypes and test therapeutic interventions.
What is the structure of OSTα/β?
Recent cryo-EM studies revealed a unique fold for OSTα/β that enables bile acid transport.
Why is organic acid transport important for pharmacology?
Many drugs are organic acids that require transporters for absorption, distribution, and elimination, affecting efficacy and toxicity.
Conclusion
Organic acid transport (GO:0015849) is a cornerstone of cellular metabolism and physiology, governing the movement of bile acids, hormones, and drugs. The diverse family of transporters involved, from SLC22A7 to OSTα/β, underscores the complexity and specificity of this process. Dysregulation leads to significant human diseases, making these transporters attractive therapeutic targets. CRISPR-based models are indispensable for dissecting their functions and validating candidate genes. EDITGENE's comprehensive services empower researchers to generate precise cell models and accelerate discoveries in organic acid transport biology.
References
- 1. Boyer JL. 2013. Bile formation and secretion.. Compr Physiol 3(3):1035-78 PMID: 23897680
- 2. Mathialagan S et al.. 2020. Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7).. Biochem Pharmacol 174:113829 PMID: 32001236
- 3. Gyimesi G et al.. 2023. Transporter-Mediated Drug Delivery.. Molecules 28(3) PMID: 36770817
- 4. Suga T et al.. 2019. Characterization of conjugated and unconjugated bile acid transport via human organic solute transporter α/β.. Biochim Biophys Acta Biomembr 1861(5):1023-1029 PMID: 30853579
- 5. Groeneweg S et al.. 2020. Thyroid Hormone Transporters.. Endocr Rev 41(2) PMID: 31754699
- 6. Beaudoin JJ et al.. 2020. Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions.. Toxicol Sci 176(1):34-35 PMID: 32294204
- 7. Yang X et al.. 2026. Structures of Ostα/β reveal a unique fold and bile acid transport mechanism.. Nature 651(8104):260-267 PMID: 41606328
- 8. Roch-Ramel F. 1998. Renal transport of organic anions.. Curr Opin Nephrol Hypertens 7(5):517-24 PMID: 9818198
